Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2006-12-11
2009-11-17
Zucker, Paul A (Department: 1621)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
C564S196000
Reexamination Certificate
active
07619006
ABSTRACT:
Novel chemical conjugates of psychotropic drugs and organic acids, uses thereof in the treatment of psychotic and/or proliferative disorders and diseases and as chemosensitizing agents, and their syntheses are disclosed. The organic acids are selected to reduce side effects induced by the psychotropic drugs and/or to exert an anti-proliferative activity.
REFERENCES:
patent: 2914528 (1959-11-01), Craig
patent: 2944053 (1960-07-01), Edgerton
patent: 2969358 (1961-01-01), Cusic
patent: 3956493 (1976-05-01), Yale
patent: 3966930 (1976-06-01), Buus et al.
patent: 4629691 (1986-12-01), Collins et al.
patent: 5051448 (1991-09-01), Shashoua
patent: 5525727 (1996-06-01), Bodor
patent: 5994392 (1999-11-01), Shashoua
patent: 6121325 (2000-09-01), Chen et al.
patent: 6197764 (2001-03-01), Bradley et al.
patent: 6569853 (2003-05-01), Borisy et al.
patent: 2002/0010208 (2002-01-01), Shashoua et al.
patent: 2004/0242570 (2004-12-01), Nudelman et al.
patent: 2006/0058219 (2006-03-01), Miller
patent: 2006/0142181 (2006-06-01), Miller
patent: 2007/0099977 (2007-05-01), Nudelman et al.
patent: 0361485 (1990-04-01), None
patent: 8707175 (1987-10-01), None
patent: 829 246 (1960-03-01), None
patent: 60-72868 (1994-03-01), None
patent: WO 97/44063 (1997-11-01), None
patent: WO 02/28881 (2002-04-01), None
patent: WO 02/43652 (2002-06-01), None
patent: WO 03/026563 (2003-04-01), None
patent: WO 03/061656 (2003-07-01), None
patent: WO 2005/032474 (2005-04-01), None
patent: WO 2005/092392 (2005-10-01), None
patent: WO 2006/027711 (2006-03-01), None
Degrand et al, Journal of Organic Chemistry, Synthesis of Nitroxides for Use as Procationic Labels Their Incorporation into Nafion Films, 1993, 58 pp. 2573-2577.
Budavari et al. “The Merck Index”, Merck & Co., USA, 12th Ed., 1996. p. THER-8, First Col., 6th Line From the Bottom, 2nd Col., Line 13.
Budavari et al. “The Merck Index”, Merck & Co., USA, 12th Ed, 1996. p. 1260, § 1.
Budavari et al. “The Merck Index”, Merck & Co., USA, 12th Ed., 1996. p. 1246, Last §.
Capasso et al. “Anticonvulsive Activity of a New GABA Mimetic Drug”, European Neuropsychopharmacology, 7: 57-63, 1997.
Fingl et al. “General Principles”, The Pharmacological Basis of Therapeutics, Chap.1: 1-46, 1975.
Geyer et al. “Animal Behavior Models of the Mechanisms Underlying Antipsychotic Atypicality”, Progress in Neuro-Psychopharmacology & Biological Psychiatry, 27: 1071-1079, 2003.
Hadad et al. “Pharmacokinetic Analysis and Antiepileptic Activity of N-Valproyl Derivatives of GABA and Glycine”, Pharmaceutical Research, 112(6): 905-910, 1995.
Köpf-Maier et al. “An Organoid Culture Assay (OCA) for Determining the Drug Sensitivity of human Tumors”, Int. J. Cancer, 51: 99-107, 1992.
Lloyd et al. “The Potential Use of GABA Agonists in Psychiatric Disorders: Evidence From Studies With Progabide in Animal Models and Clinical Trials”, Pharmacology Biochemistry & Behavior, 18: 957-966, 1983.
McCaffrey et al. “A Rapid Fluorometric DNA Assay for the Measurement of Cell Density and Proliferation In Vitro”, In Vitro Cellular Development Biology, 24(3): 247-252, 1988. Abstract.
Nicoletti et al. “A Rapid and Simple Method for Measuring Thymocyte Apoptosis by Propidium Iodide Staining and Flow Cytometry”, Journal of Immunological Methods, 139: 271-279, 1991.
Nordenberg et al. “Effects of Psychotropic Drugs on Cell Proliferation and Differentiation”, Biochemical Pharmacology, 58: 1229-1236, 1999.
Pouzet et al. “Effects of the 5-HT7 Receptor Antagonist SB-258741 in Animal Models for Schizophrenia”, Pharmacology, Biochemistry and Behavior, 71: 655-665, 2002.
Quadri et al. “Effects of Centrally Acting Drugs on Serum Prolactin Levels in Rhesus Monkeys”, Neuroendocrinology, 27(3-4): 136-147, 1978. Abstract.
Rephaeli et al. “Observation of Sequence-Dependent Interaction Between Prodrugs of Carboxylic-Acid-Esters and Doxorubicin in Cancer Cells”, Proceedings of the American Association for Cancer Research, Annual Meeting, 40: 592-, 1999. Abstract. & 90th Annual Meeting of the American Association for Cancer Research, Philadelphia, PA, USA, 1999.
Scriba “Phenytoin-Lipid Conjugates as Potential Prodrugs of Phenytoin”, Archiv der Pharmazie, VCH—Verlagsgesellschaft MBH, Weinheim, DE, 326(8): 477-481, 1993. Scheme 1, p. 147.
Scriba et al “Anticonvulsant Activity of Phenytoin-Lipid Conjugates, A New Class of Phenytoin Prodrugs”—Journal of Pharmaceutical Pharmacology, 47: 197-203, 1996. Scheme 1, p. 198, Abstract.
Scriba et al. “Synthesis and Anticovulsant Activity of N-Benzyloxycarbonyl-Amino Acid Prodrugs of Phenytoin”, J. Pharm. Pharmacol., 51: 549-553, 1999.
Shalitin et al. “The Effect of Angiotensin II on Myosin Heavy Chain Expression in Cultured Myocardial Cells”, In Vitro Cellular Development Biology—Animal, 32: 573-578, 1996.
Toth “A Novel Chemical Approach to Drug Delivery: Lipidic Amino Acid Conjugates”, Journal of Drug Targeting, 2(3): 217-239, 1994. p. 223, col. II, 3rd §.
Wolffe “Transcriptional Control. Sinful Repression”, Nature, 387: 16017, 1997.
Worms et al. “Dopamine-Like Activities of An Aminopyridazinde Derivative, CM 30366: A Behavioural Study”, Naunyn-Schmiedeberg's Archives of Pharmacology, 334: 246-252, 1986.
Yogev-Falach et al. “The Importance of Propargylamine Moiety in the Anti-Parkinson Drug Rasagiline and Its Derivatives in MAPK-Dependent Amyloid Precursor Protein Processing”, The FASEB Journal, 17: 2325-2327, 2003. Abstract.
Zaugg et al. “Modification of Hemoglobin With Analogs of Aspirin”, The Journal of Biological Chemistry, 255(7): 2816-2821, 1980.
“New Edition of Pharmaceutics”, People's Hygiene Publishing House, 14: 178, 1998. Abstract.
Office Action Dated Feb. 27, 2009 From the Israeli Patent Office Re.: Application No. 161083 and Its Translation Into English.
Chinese Official Action Dated Aug. 8, 2008 From Patent Office of the Peoples Republic of China Re.: Application No. 02823600.9.
International Preliminary Examination Report Dated Oct. 12, 2006 From the International Searching Authority by Patent Cooperation Treaty Re.: Application No. PCT/IL2005/000341.
Notice of Allowance Dated Mar. 11, 2008 From the US Patent And Trademark Office Re.: U.S. Appl. No. 10/808,541.
Office Action Dated Feb. 1, 2007 From the US Patent and Trademark Office Re.: U.S. Appl. No. 10/808,541.
Office Action Dated Apr. 17, 2008 From the US Patent and Trademark Office Re.: U.S. Appl. No. 11/636,594.
Office Action Dated Mar. 30, 2006 From the US Patent and Trademark Office Re.: U.S. Appl. No. 10/808,541.
Official Action Dated Feb. 14, 2008 From the Government of India Patent Office Re.: Application No. 642/CHENP/2004-SPS.
Official Action Dated May 15, 2008 From the Government of India Patent Office Re.: Application No. 642/CHENP/2004-SPS.
Official Action Dated Oct. 31, 2008 From the US Patent Office Re.: U.S. Appl. No. 12/005,342.
Gil-Ad Irit
Nudelman Abraham
Rephaeli Ada
Weizman Abraham
Bar-Ilan University
Ramot At Tel Aviv University Ltd.
Zucker Paul A
LandOfFree
Conjugated psychotropic drugs and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Conjugated psychotropic drugs and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Conjugated psychotropic drugs and uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4095481